Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the cosentyx drug market?
The market size for the drug Cosentyx has seen significant growth in the recent past. Projections indicate that it will increase from $5,195.11 million in 2024 to $5,683.20 million in 2025, reflecting a compound annual growth rate (CAGR) of 9.4%. The expansion in the historic timeframe has been facilitated by factors such as FDA sanction and initial market entrance, demonstrated clinical effectiveness and safety profile, a transition towards biologics, real-world statistical evidence, enduring advantages, and worldwide regulatory authorizations.
What will be the cosentyx drug market size in the future?
Expectations are high for the Cosentyx drug market, with sturdy growth predicted over the next few years. The market value is set to reach $8,030.80 million come 2029, showing an impressive compound annual growth rate (CAGR) of 9.0%. Several factors are contributing to this prospective growth within the forecast period. These include a rising number of autoimmune diseases, expanding approved indications, advancements in the field of biologic therapies, advantageous reimbursement policies, and strong clinical outcomes. The anticipated trends during the forecast period comprise the expanded use for autoimmune diseases, a shift towards personalized medicine, and a dominance of subcutaneous administration coupled with plentiful R&D in new therapeutic areas.
Get your cosentyx drug market report here!
https://www.thebusinessresearchcompany.com/report/cosentyx-drug-global-market-report
What main drivers are fueling expansion in the cosentyx drug market?
The escalating occurrence of autoimmune diseases is predicted to fuel the expansion of the cosentyx market in the future. Autoimmune diseases are characterized by the body’s immune system erroneously attacking its own healthy cells and tissues. The increased prevalence of these diseases can be traced back to genetic factors, environmental elements like infections and pollution, and changes in lifestyle, including amplified stress levels and changes in diet. Cosentyx (secukinumab) assists patients dealing with autoimmune diseases by focusing on and impeding interleukin-17A, a critical cytokine in the inflammation process, thus lessening symptoms and effectively managing conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. For example, data from Public Health Scotland, a Scotland-based national organization, showed that in July 2023, the number of newly diagnosed patients with multiple sclerosis (MS) rose to 87.2%, up from 85.7%, with 491 new cases reported in total, leading to a total of 6,359 in 2022. Hence, the proliferating occurrence of autoimmune diseases is propelling the growth of the cosentyx market. It is also anticipated that the expanding healthcare expenditure will boost the cosentyx market in the future. Healthcare expenditure pertains to the total amount used on healthcare products and services, including personal healthcare, preventive measures, and public health activities, geared towards enhanced health outcomes over a set period. The surge in healthcare expenditure is a result of factors such as an aging populace, chronic illnesses, advanced medical technology, high medication prices, inefficient payment methods, and a growing demand for services. The expense for Cosentyx is primarily focused on managing moderate to severe cases of psoriasis, psoriatic arthritis, and ankylosing spondylitis, thereby improving patient outcomes via targeted biologic therapy. According to a report from the Office For National Statistics, a UK government agency, in May 2024, the total healthcare expenditure witnessed a 5.6% nominal increase from 2022 to 2023, contrasting with a growth rate of just 0.9% in 2022. Moreover, the total long-term health and social care expenditure experienced a real-terms increase of 2.8% in 2022. Hence, the burgeoning healthcare expenditure is catalyzing growth in the cosentyx market.
What key areas define the segmentation of the global cosentyx drug market?
The cosentyx drugmarket covered in this report is segmented –
1) By Indication: Hidradenitis suppurativa; Psoriatic arthritis; Ankylosing spondylitis; Plaque Psoriasis
2) By Route Of Administration: Subcutaneous injection; Intravenous infusion
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19891&type=smp
Who are the dominant players expanding their reach in the cosentyx drug market?
Major companies operating in the cosentyx drug market include Novartis AG
How are evolving market trends shaping cosentyx drug Strategies?
A prevailing trend within the cosentyx drug industry is primarily centered on progressing advanced treatments such as the biological therapy options. The aim is to address the unmet requirements in the healthcare sector, increase the efficiency of treatments, and offer targeted therapies to manage persistent autoimmune disorders. This approach fortifies their market standing and serves the increasing patient demographics. Biological therapies are advanced treatments originating from living organisms or their cells, specifically targeting components of the immune system like interleukin-17A to alter inflammatory reactions and effectively treat autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. In October 2023, Novartis AG, a Swiss-based pharmaceutical company earned FDA approval for Cosentyx (secukinumab). This marked the introduction of a novel biologic treatment option for moderate to severe hidradenitis suppurativa (HS) in nearly ten years. This approval signifies a noteworthy progression in treating HS, a chronic and frequently incapacitating skin condition typified by painful lumps leading to scarring and causing psychological distress.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19891
Which regions are emerging as leaders in the cosentyx drug market?
North America was the largest region in the cosentyx drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cosentyx drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Arthritis Monoclonal Antibodies Global Market Report 2025
Biosimilar Monoclonal Antibodies Global Market Report 2025
Arthritis Monoclonal Antibodies Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
